Canakinumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL-1β |
| Clinical data | |
| Trade names | Ilaris |
| Other names | ACZ885, ACZ-885 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a622024 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous, subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6452H9958N1722O2010S42 |
| Molar mass | 145157.20 g·mol−1 |
| (what is this?) (verify) | |
Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including adult-onset Still's disease, gout flares.[6][7][8] It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.[9]
Common side effects include infections (colds and upper respiratory tract infections), abdominal pain and injection-site reactions.[4][5][6]
- ^ Rondeau JM, Ramage P, Zurini M, Gram H (2015). "The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β". mAbs. 7 (6): 1151–1160. doi:10.1080/19420862.2015.1081323. PMC 4966334. PMID 26284424.
- ^ "AusPAR: Canakinumab". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 7 March 2025.
- ^ "Ilaris (Novartis Pharmaceuticals Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 19 February 2025. Retrieved 7 March 2025.
- ^ a b Cite error: The named reference
Ilaris FDA labelwas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Ilaris EPARwas invoked but never defined (see the help page). - ^ a b "FDA Approves First Treatment for Adult Onset Still's Disease, a Severe and Rare Disease". U.S. Food and Drug Administration (FDA) (Press release). 16 June 2020. Archived from the original on 17 June 2020. Retrieved 16 June 2020. This article incorporates text from this source, which is in the public domain.
- ^ Dhimolea E (2010). "Canakinumab". mAbs. 2 (1): 3–13. doi:10.4161/mabs.2.1.10328. PMC 2828573. PMID 20065636.
- ^ "FDA Approves Canakinumab for Gout Flares". Medscape. Retrieved 1 September 2023.
- ^ Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. (June 2009). "Use of canakinumab in the cryopyrin-associated periodic syndrome". The New England Journal of Medicine. 360 (23): 2416–2425. doi:10.1056/NEJMoa0810787. PMID 19494217.